Dexmedetomidine did not reduce the effects of tourniquet-induced ischemia-reperfusion injury during general anesthesia  by Bostankolu, Evrim et al.
Kaohsiung Journal of Medical Sciences (2013) 29, 75e81Available online at www.sciencedirect.com
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLE
Dexmedetomidine did not reduce the effects of
tourniquet-induced ischemia-reperfusion injury during
general anesthesiaEvrim Bostankolu a, Hilal Ayoglu a,*, Serhan Yurtlu a, Rahsan Dilek Okyay a,
Gu¨lay Erdogan a, Yeliz Deniz a, Volkan Hanci a, Murat Can b, Isil Ozkocak Turan aaDepartment of Anesthesiology and Reanimation, Zonguldak Karaelmas University, Zonguldak, Turkey
bDepartment of Biochemistry, School of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey
Received 4 August 2011; accepted 23 November 2011






capacity* Corresponding author. Bahcelievle
E-mail address: periayogluzku@yah
1607-551X/$36 Copyright ª 2012, Kao
http://dx.doi.org/10.1016/j.kjms.201Abstract Ischemia reperfusion injury causes the release of free oxygen radicals. Free oxygen
radicals initiate the production of toxic metabolites, such as malondialdehyde (MDA), through
the lipid peroxidation of cellular membranes. Following lipid peroxidation, the antioxidant
enzyme system is activated against reactive oxygen species (ROS) and attempts to protect cells
from oxidative damage. There is a balance between the scavenging capacity of antioxidant
enzymes and ROS. Because of this balance, the total antioxidant capacity (TAC) measurement
is a sensitive indicator of the overall protective effects of the antioxidants. Alpha2 receptor
agonists are effective in preventing hemodynamic reactions during extremity surgeries by pre-
venting the release of catecholamines secondary to tourniquet application. They have also
been shown to possess preventive effects in various ischemia-reperfusion injury models. In
our study, we examined the effects of dexmedetomidine on tourniquet-induced ischemia-re-
perfusion injury in lower extremity surgeries performed under general anesthesia. The effects
of dexmedetomidine were measured with serum MDA and TAC levels. We studied 60 adult
American Society of Anesthesiologists (ASA) physical status I or II patients undergoing one-
sided lower extremity surgery with tourniquet. The patients were randomly divided into two
groups. Group D was administered a dexmedetomidine infusion at a rate of 0.1 mg/kg/
minute1 for 10 minutes prior to induction and then at 0.7 mg/kg/hour1 until 10 minutes
before the end of the operation. The control group (Group C) received a saline infusion of
the same amount and for the same period of time. General anesthesia was induced with thio-
pental, fentanyl, and rocuronium and maintained with nitrous oxide and sevoflurane in both
groups. Venous blood samples were obtained before the administration of the study drugs
(basal) at 1 minute before tourniquet release and at 5 and 20 minutes after tourniquet releaser mah, Gul Sok, Bahadir apt, Da:18, Site, Zonguldak, Turkey.
oo.com (H. Ayoglu).
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76 E. Bostankolu et al.(ATR). In both groups, MDA levels decreased at 5 and 20 minutes ATR when compared with the
basal values (p< 0.05). TAC levels decreased at 1 and 5 minutes ATR and then returned to
basal values at 20 minutes ATR (p< 0.05). In reference to the prevention of lipid peroxidation
in tourniquet-induced ischemia-reperfusion injury, the results from the two groups in our study
showed that dexmedetomidine did not have an additional protective role during routine
general anesthesia.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Tourniquets in the proximal area are widely used in
extremity surgeries to control intraoperative bleeding [1].
Ischemia occurs in the extremity following tourniquet
inflation, and reperfusion occurs after deflation because of
the re-establishment of blood flow [1]. The hemodynamic
and metabolic changes that occur with tourniquet place-
ment depend on the tourniquet phase (inflation/deflation),
the duration of tourniquet placement, the size of the
ischemic area, the type of anesthesia administered, and
the cardiovascular condition of the patient [2]. The
removal of the tourniquet initiates the event of ischemia
reperfusion injury through the sequestration of oxygenated
blood cells in the extremity, which leads to the appearance
of free oxygen radicals [3]. Reactive oxygen species (ROS)
that appear with reperfusion injury damage cellular struc-
tures through the process of the lipid peroxidation of
cellular membranes and yield toxic metabolites such as
malondialdehyde (MDA) [4]. As an important intermediate
product in lipid peroxidation, MDA is used as a sensitive
marker of ischemia-reperfusion injury [5]. ROS-induced
tissue injury is triggered by various defense mechanisms
[6]. The first defense mechanisms include the antioxidant
enzymes of superoxide dismutase (SOD), catalase (CAT),
and glutathione peroxidase (GPx) [6]. These enzymes
catalyze ROS into less reactive substances [7,8]. There is
a balance between ROS and the scavenging capacity of
antioxidant enzymes. Total antioxidant capacity (TAC) is
a test that measures all antioxidants rather than measuring
them separately and revealing their relationships [9]. TAC is
a functional outcome of both the oxidation capacity and
the consumption rate of antioxidants during oxidative
stress [10]. Both clinical and experimental studies focusing
on the reduction of free radical-mediated reperfusion
injury due to tourniquet-induced ischemia report that
tissue injury may be controlled through the use of immu-
nosuppressives, corticosteroids, anesthetic agents, various
anesthesia methods and antioxidants [7,8,11,12]. As
a selective alpha2 receptor agonist, dexmedetomidine has
high lipid resolution and has analgesic, sedative and anes-
thetic effects [13]. Alpha2 receptor agonists are effective in
preventing hemodynamic reactions in extremity surgeries
where a tourniquet is used because they prevent the
release of catecholamines and have been shown to possess
preventive effects in various ischemia-reperfusion injury
studies [13e15].
We hypothesized that dexmedetomidine might protect
against ischemia-reperfusion injury in extremity surgeries
performed under general anesthesia with the use ofa tourniquet. The primary outcome variables were deter-
mined with serum MDA and TAC values measured at bsal, at
1 minute before and at 5 and 20 minutes after the release
of the tourniquet.Methods
Ethical approval for this study (Ethical Committee N 2008/
17) was provided by the Ethical Committee of Zonguldak
Karaelmas University Hospitals, Zonguldak, Turkey (Chair-
person Assoc. Prof. B.D Gun) on November 20, 2008.
After gaining the approval of the university ethics
committee, written informed consent was obtained from
the study participants. The participants enrolled in our
study included patients who were scheduled for an elective
lower extremity operation under general anesthesia using
a one-sided tourniquet who did not have a previous history
of liver and renal disease, diabetes mellitus, smoking,
antioxidant treatment or an allergy to any of the drugs used
in the study. In the preanesthetic assessment, 60 American
Society of Anesthesiologists (ASA) physical status I or II
patients 18-65 years of age and weighing 60e100 kg were
included in the study. Cases with tourniquet times of less
than 60 minutes or longer than 150 minutes were excluded.
All patients received 0.07 mg/kg intramuscular midazolam
30 minutes prior to the operation.
In the operating room, standard procedures for moni-
toring patients under anesthesia were performed. Vascular
access froma large cubital veinwas achievedwith a 16-gauge
(G) needle. Basal blood samples were drawn for the deter-
mination of serum MDA and TAC levels prior to the adminis-
tration of study drugs (T0). For the drip infusion, a 20-G
needle was used for vascular access in the other arm.
Patients were randomly assigned by sealed envelope to one
of two groups: Group D (nZ 30) or Group C (nZ 30). Group D
received dexmedetomidine (Precedex 2 ml/200 mg, Medi-
tera, Izmir, Turkey) at an infusion rate of 0.1 mg/kg/minute1
for 10 minutes prior to induction and at a rate of 0.7 mg/kg/
hour1 until 10 minutes before the end of the operation. The
control group (Group C; nZ 30) received a saline solution of
the same volume and for the same amount of time. Both
groups were administered thiopental 5 mg/kg, fentanyl
1 mg/kg, and rocuronium bromide 0.6 mg/kg at the end of 10
minutes for anesthesia induction. Anesthesia was main-
tained in both groups with 4 Lminute1 50% N2O for oxygen
and rocuroniummaintenance. The end tidal (ET) sevoflurane
concentration was 1.5%, and the ETCO2 was 35 mmHg.
Following intubation, the affected extremity was elevated
andwrappedwith an Esmarch bandage, and a tourniquetwas
Table 1 Demographic data, American Society of Anes-
thesiologists (ASA) physical status groups, operation, and









ASA (I/II) 24/6 26/4 0.488a
Age (yr) 38.6 10.3 33.8 10.4 0.075b
Height (cm) 169.5 7.6 170.7 8.6 0.557b
Weight (kg) 76.5 11.6 71.9 11.9 0.135b
Operation
times (min)
112.2 36.7 112.4 40.5 0.979b
Tourniquet
times (min)
86.1 26.4 82.2 22.3 0.539b
Data presented as n or mean standard deviation. pZ com-
pared between groups.
a Chi-square test.
b Student t test.
Dexmedetomidine for ischemia-reperfusion 77applied at a pressure of 300 mmHg. Intraoperative arterial
blood pressure and heart rate values of 25% less than basal
were considered hypotensive and bradycardic. Intravenous
(IV) ephedrine 5 mg was administered in the setting of
hypotension, and atropine 0.5 mg IV was administered in the
setting of bradycardia. When intraoperative bleeding
occurred, volume replacement was initiated with saline
instead of blood products. The patient demographics; the
operation and tourniquet times; the dosages of fentanyl,
rocuronium, ephedrine, and atropine that were adminis-
tered; the amount of bleeding; and the amount of saline used
were recorded. Hemodynamic data were recorded at T0,
after the induction of anesthesia (T1), before tourniquet
placement (T2), 1minute after tourniquet placement (T3), 1
minute before tourniquet release (T4), 5 minutes after
tourniquet release (ATR) (T5), and 20 minutes ATR (T6).
Blood samples for MDA and TAC levels were drawn at T0, T4,
T5, and T6. The neuromuscular block was antagonized with
neostigmine 0.05 mg kg1 and atropine 0.02 mg kg1, and
the total dose of neostigmine was recorded. The blood
samples were centrifuged at 4,000 rpm for 5 minutes for
serum separation and were then stored at 80C.
Malondialdehyde measurement
MDA levels were analyzed with the HPLC method using
a commercial MDA kit (Immunodiagnostic, Bensheim,
Germany) and the HPLC tool (Shimadzu, Kyoto, Japan).
After the mixture was placed in vials, 20 ml samples were
injected into the SIL 20A automatic sampling system
(Shimadzu, Kyoto, Japan) in the HPLC tool at a flow rate of
1 ml/minute1. A 5-minute mobile phase flow was ensured
from the reverse phase C18 (60 mm, 125  4 mm) column
(Phenomenex Gemini, California, USA) and 254 nm wave-
length readings were performed in the RF 10XL florescent
detector (Shimadzu, Kyoto, Japan). From the pique areas
obtained, MDA concentrations were measured as mmol/L.
The detection limit was 0.15 mmol/L, the intra-assay coef-
ficient of variation (CV) was 4.8e6.1%, and the inter-assay
CV was less than 5.7e6.9%.
Total antioxidant capacity measurement
TAC levels were measured with Randox laboratory kits
(Randox, Antrim, UK) in the spectrophotometer. The prin-
ciple of this test is based on colorimetric measurement
where 2,2-azino-di-3-ethylbenzthiazoline sulphonate (ABTSr)
is incubated with peroxidase (metmyoglobin) and H2O2.
ABTSrþ, the radical cation of ABTSr, is created. The addi-
tion of antioxidants inhibits the formation of ABTSrþ. The
color change that results is proportionate to the antioxidant
concentration. The absorbance of the blue-green color we
obtained was measured at (A2) 37C and 600 nm in the
spectrophotometer. The results are reported as mmol/L.
The reference range for the laboratory was 1.30e
1.77 mmol/L.
Power analysis
The major outcome of our study was to determine the
serum MDA levels. Sample size estimation was based on themean and standard deviation of a similar study performed
by Sarıcaoglu et al. [11]. Using the MDA levels (2.7 0.27
baseline MDA levels for the control group) determined by
Sarıcaoglu et al. [11] to detect a 10% change in MDA levels
with an a error of 0.05 and a power of 95%, we calculated
that the sample size for our study should include at least
24 patients per group. Predicting a dropout rate of
approximately 25%, we included 30 patients in each group.
The sample size estimation was performed using the Power
Calculator (UCLA Department of Statistics, http://www.
stat.ubc.ca/_rollin/stats/ssize).
Statistical analysis
The data were analyzed with SPSS for Windows 13.0
(SPSS, Chicago, IL, USA). Mean values were shown as the
mean standard deviation. The Chi-square test was used
for the comparison of quantitative data, such as gender and
ASA score distributions. The continuous variables of age,
height, body mass, operation times, tourniquet times,
amount of bleeding, amount of fluid, and the drug dosages
used in the groups were compared using Student t test.
Hemodynamic, MDA, and TAC differences among the groups
and time-bound changes were analyzed by two-way anal-
ysis of variance in repeated measures and the Bonferroni
test. Analysis results were evaluated in the 95% confidence
interval, and p< 0.05 indicated statistical significance.
Results
When the demographic data of the study groups, ASA
groups, operation, and tourniquet times were compared,
significant differences were not observed (Table 1). In the
intraoperative period, the amount of rocuronium bromide
administered was less in Group D (pZ 0.022). The amount
of ephedrine used was higher in Group D (pZ 0.002). No
significant difference was found between the groups in
reference to the dosages of fentanyl, atropine, neostigmine
Figure 1. Changes in systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) values (mmHg) of control group
(Group C) and dexmedetomidine group (Group D) according to
time (data presented as mean standard deviation). *p< 0.05
between Group C and Group D. **p< 0.05 for Group C,
compared within itself with basal value at T0. yp< 0.05 for
Group D, compared within itself with basal value at T0 (two-
way analysis of variance in repeated measures and the Bon-
ferroni test). T0Z before the study drug administration;
T1Z after induction; T2Z before the tourniquet application;
T3Z 1 minute after the tourniquet application; T4Z 1 minute
before tourniquet release; T5Z 5 minutes after tourniquet
release; T6Z 20 minutes after tourniquet release.
78 E. Bostankolu et al.administered; the amount of saline infused; and the
amount of intraoperative bleeding (Table 2).
A significant difference was observed between the
groups with respect to systolic and diastolic arterial pres-
sure values (p< 0.05; Fig. 1). The heart rate of patients in
Group D was significantly reduced compared to Group C at
T1, T2, and T6 (p< 0.05; Fig. 2).
The groups did not display an overall significant differ-
ence in MDA values (pZ 0.995). However, MDA values over
time in Groups D and C showed significant differences
(p< 0.001). In both groups, MDA values at T4, T5, and T6
were lower than basal MDA values at T0 with the decreased
values at T5 and T6 significantly different when compared
with T0 (Fig. 3 and Table 3).
Overall, no significant difference was observed between
the TAC values of the groups (pZ 0.411). However, intra-
group TAC values were significantly different over time
(p< 0.001). In both groups, the decrease in T4 and T5
values was significantly different when compared with T0
basal values, but the significance was not observed at T6
(Fig. 4 and Table 4).
A significant difference was not observed between the
SpO2 values of the groups.
Discussion
The aim of our study was to evaluate the effects of dex-
medetomidine on tourniquet-induced ischemia-reperfusion
injury during general anesthesia by measuring MDA and TAC
levels when dexmedetomidine was added to the general
anesthesia. The main findings of our study demonstrate
that serum MDA levels were decreased when compared to
basal values at 5 and 20 minutes ATR and that TAC was
lower than basal values at 1 minute before and at 5 minutes
ATR and reached the basal level at 20 minutes ATR.
However, these findings were similar to the results obtained
from the group that was not given dexmedetomidine.
Pneumatic tourniquets used in extremity surgery leads
to the development of neutrophil activation, the release of
reactive oxygen products and vasoactive substances as
a result of muscle ischemia, which results in hypoxic
cellular change, anaerobic glycolysis and reperfusion injury
[16,17]. The release of free oxygen radicals causes lipidTable 2 Amounts of rocuronium, fentanyl, ephedrine,
atropine, neostigmine, saline consumptions, and intra-






Rocuronium (mg) 66.2 17.1 56.0 16.4 0.022
Fentanyl (mg) 78.0 13.8 71.5 13.9 0.073
Ephedrine (mg) 0.7 2.9 4.3 5.4 0.002
Atropine (mg) 0.4 0.3 0.4 0.3 0.640
Neostigmine (mg) 1.2 0.6 1.1 0.7 0.848
Saline (mL) 1491.7 469.8 1480 469.3 0.924
Bleeding (mL) 51.0 74.8 29.3 70.3 0.252
Data presented as mean standard deviation. pZ compared
between groups (Student t test).peroxidation and initiates the development of MDA,
a strong indicator of free radical formation [18]. Previous
studies have been concerned with the effects of various
anesthetic agents and anesthetic methods on tourniquet-
induced ischemia-reperfusion injury. These studiesFigure 2. Changes in heart rate values (beat/minute) of
control group (Group C) and dexmedetomidine group (Group D)
according to time (data presented as mean standard devia-
tion). *p< 0.05 between Group C and Group D (two-way anal-
ysis of variance in repeated measures and the Bonferroni test).
T0Z before the study drug administration; T1Z after induc-
tion; T2Z before the tourniquet application; T3Z 1 minute
after the tourniquet application; T4Z 1 minute before tour-
niquet release; T5Z 5 minutes after tourniquet release;































Figure 3. Changes in serum malondialdehyde (MDA) levels
(mmol/L) of control group (Group C) and dexmedetomidine
group (Group D) according to time (data presented as mean -
 standard deviation). *p< 0.05 for Group C, compared within
itself with basal value at T0. **p< 0.05 for Group D, compared
within itself with basal value at T0 (two-way analysis of vari-
ance in repeated measures and the Bonferroni test).
T0Z before the study drug administration; T4Z 1 minute
before tourniquet release; T5Z 5 minutes after tourniquet
release; T6Z 20 minutes after tourniquet release.
Figure 4. Changes in serum total antioxidant capacity (TAC)
levels (mmol/L) of control group (Group C) and dexmedeto-
midine group (Group D) according to time (data presented as
mean standard deviation). *p< 0.05 for Group C, compared
within itself with basal value at T0. **p< 0.05 for Group D,
compared within itself with basal value at T0 (two-way analysis
of variance in repeated measures and the Bonferroni test).
T0Z before the study drug administration; T4Z 1 minute
before tourniquet release; T5Z 5 minutes after tourniquet
release; T6Z 20 minutes after tourniquet release.
Dexmedetomidine for ischemia-reperfusion 79suggested that anesthetic agents inhibit leukocyte func-
tion, but these agents may also act as antioxidants by
preventing high ROS formation and decreasing lipid perox-
idation [19,20].
Alpha2-receptors are found on neutrophils [21].
Alpha2-adrenergic receptor agonists have been reported
to modulate the balance between proapoptotic and
antiapoptotic proteins and neutrophil functions in
ischemia-reperfusion injury. Studies have also shown that
alpha2-adrenergic receptor agonists prevent oxidative
stress and vasospasm because their effects may take the
place of glutamate, catecholamine release inhibition and
N-methyl-D-aspartate (NMDA) receptor blockade [22,23].
Dexmedetomidine has also been shown to inhibit inflam-
matory responses with effects ranging from the regulation
of cytokine production by macrophages and monocytes to
endotoxemia [24,25].
Thiopental is an anesthetic agent with high oil solubility
and an antioxidant effect. Thiopental suppresses lipid
peroxidation, and at concentrations used in clinic, theTable 3 Changes in serum malondialdehyde levels (mmol/







T0 1.5 0.5 d 1.4 0.6 d 0.383
T4 1.3 0.4 0.125 1.3 0.5 0.125 0.934
T5 1.1 0.4 <0.001 1.2 0.5 <0.001 0.563
T6 0.8 0.2 <0.001 0.9 0.3 <0.001 0.494
Data presented as mean standard deviation.
p1Z groups compared within itself with basal value at T0;
pZ compared between groups (two-way analysis of variance in
repeated measures and the Bonferroni test).
T0Z before the study drug administration; T4Z 1 minute
before tourniquet release; T5Z 5 minutes after tourniquet
release; T6Z 20 minutes after tourniquet release.agent suppresses reactive oxygen types derived from
neutrophils. Depending on the dosage, thiopental also
decreases leukocyte leukomotor activity, reduces MDA
levels in the prevention of renal ischemia-reperfusion
injury, and exhibits antioxidant activity [26,27]. Aldemir
et al. [28] studied free radical formation in two types of
general anesthesia that used the combination of fentanyl-
thiopental-halothane or propofol-fentanyl in cases of
knee arthroplasty with tourniquet-induced ischemia-
reperfusion injury. The study showed that MDA levels
decreased ATR when compared to baseline in the both
types of general anesthesia. However, there was a statisti-
cally significant decrease only in propofol group.
Sevoflurane has been shown to prevent myocardial
dysfunction and necrosis in the reperfusion phase after
myocardial ischemia and to positively affect oxidative
stress and antioxidant mechanisms by causing less lipid
peroxidation in laparoscopic cholecystectomy [29,30].Table 4 Changes in serum total antioxidant capacity
levels (mmol/L) of control group and dexmedetomidine






T0 1.2 0.2 d 1.3 0.3 d 0.291
T4 1.0 0.6 <0.001 0.9 0.4 <0.001 0.796
T5 0.9 0.4 <0.001 1.0 0.4 <0.001 0.353
T6 1.1 0.4 0.171 1.2 0.4 0.171 0.652
Data presented as mean standard deviation.
p1Z groups compared within itself with basal value at T0;
pZ compared between groups (two-way analysis of variance in
repeated measures and the Bonferroni test).
T0Z before the study drug administration; T4Z 1 minute
before tourniquet release; T5Z 5 minutes after tourniquet
release; T6Z 20 minutes after tourniquet release.
80 E. Bostankolu et al.Arnaoutoglou et al. [31] studied the MDA levels between
a group of patients who received propofol maintenance
after fentanyl-propofol induction and a group of patients
who received sevoflurane after fentanyl-thiopental induc-
tion following tourniquet-induced ischemia-reperfusion
injury in knee surgery. They found that MDA levels in the
propofol group fell when compared to basal values 30
minutes after the removal of the tourniquet. MDA levels
increased slightly in the sevoflurane group.
Turan et al. [32] studied the effects of three different
models of propofol use in anesthesia on tourniquet-induced
ischemia-reperfusion injury in lower extremity operations.
They compared the use of the combination of fentanyl-
propofol-halothane with propofol sedation in addition to
spinal anesthesia and fentanyl-propofol used for total
intravenous anesthesia. They found that MDA levels in the
general anesthesia group were higher than basal values at
1 min prior to and at 5 and 20 minutes after removing the
tourniquet. In our study, we observed that despite our use
of a tourniquet, plasma MDA levels did not rise in either
group, while MDA levels dropped below basal values in both
groups after removing the tourniquet. We attributed MDA
levels below basal values in the control group to the anti-
oxidant effects of sevoflurane or thiopental.
Yagmurdur et al. [20] showed that in upper extremity
surgery performed with a brachial plexus block, sedation
with dexmedetomidine suppressed the elevation of MDA in
the reperfusion stage. The difference in the results of our
study might be due to the methodological differences in the
anesthesia techniques of these two studies. It should be
noted that Yagmurdur et al. [20] combined dexmedetomi-
dine with regional anesthesia, and the difference in their
findings might be the result of that combination. A previous
study demonstrated that regional anesthesia exhibits
a stronger antioxidant defense and reduces endothelial
dysfunction than general inhalational anesthesia [33].
Antioxidant enzymes such as SOD, CAT, and GPx work to
inhibit the oxidation system [6]. TAC measures all of these
antioxidant levels at one time [9]. If oxidation systems are
not activated, TAC does not increase [34]. When oxidative
stress occurs because of physiological stress, TAC falls [34].
Because the agents we used in addition to dexmedetomidine
also have antioxidant effects, it would be difficult to claim
that the recovery in TAC at 20minutes is related solely to the
general anesthetics (sevoflurane-thiopental) used.
Systemic arterial pressure rises progressively with tour-
niquet inflation in extremity surgery, and the resulting
hypertension is often resistant to anesthetic agents, anti-
hypertensive agents or an increase in the depth of anes-
thesia [35]. Tourniquet-induced hypertension has been
shown to occur as a result of the increase in catecholamine
release due to sympathetic nervous system activity [13]. In
addition, tourniquet-induced hypertension has been
attributed to the activation of NMDA receptors by periph-
eral noxious stimulation [36]. Alpha2 agonists are known to
regulate blood pressure by preventing presynaptic
noradrenaline release [37]. Preoperative clonidine has been
reported to be effective in the prevention of the hyper-
adrenergic and hyperdynamic responses that occur during
extended tourniquet application under general anesthesia
[13]. With the removal of the tourniquet, hemodynamic and
metabolic changes occur, mean arterial pressure and SpO2values tend to decrease, and PCO2 values increase [2]. We
have found that arterial blood pressure and heart rate
values were lower in the dexmedetomidine group than in
the control group. As a result, the amount of ephedrine we
used was also higher in the dexmedetomidine group. Dex-
medetomidine, at the dose range we studied, was also not
effective in the prevention of hemodynamic changes.
Interestingly, the rocuronium bromide dosages we used
were lower in the dexmedetomidine group. Talke et al. [38]
reported that dexmedetomidine caused an increase in
plasma rocuronium dosages in volunteers. Narimatsu et al.
[39] showed in a study conducted with isolated rat dia-
phragms that dexmedetomidine extended the neuromus-
cular effects of rocuronium. Because of the results of these
studies, we thought that the effects of dexmedetomidine
were worth studying.
We conclude that dexmedetomidine in addition to
general anesthesia does not have any additional preventive
benefit for lipid peroxidation in ischemia-reperfusion injury
while using thiopental-fentanyl-sevoflurane-nitrous oxide
as a general anesthetic regimen. We also conclude that
further studies are needed to clarify the effects of dex-
medetomidine on oxidative stress.
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